Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells.


BACKGROUND The wild-type herpes simplex virus type 1 (HSV-1) has strong infectivity and cytolytic effect on almost all types of mammalian cells. Genetic engineering can now restrict this cytolysis to only malignant cells. G207 is an oncolytic HSV-1 vector developed based on this strategy. MATERIALS AND METHODS We used G207 as the backbone and integrated… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.